Shanghai CP Guojian Pharmaceutical Co Ltd Products
This is a biological product, a tumor necrosis factor (TNF) blocker for the treatment of autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and psoriatic arthritis.
It has the widest use around the world and has benefitted more than 200,000 patients. In China, YISAIPU® has accounted for more than a 60-percent market share among all TNF blockers, according to the IMS. It is highly-recognized in China and has won many awards, such as National Technology Invention 2nd Place, a National Key New Product, National Patent Gold Award and National Invention Patent.
Therapeutic areas：Organ transplantation anti- rejection
Generic name：Recombinant humanized anti-CD25 monoclonal antibody injection
Indications: The first Chinese humanized monoclonal antibody injection for prophylaxis of acute organ rejection in patients receiving renal transplants. It is used as part of an immunosuppressive regimen that includes caucineurin inhibitors and corticosteroids to significantly increase the survival of transplanted organs and improve the life of patients.